Free Trial
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel Free EYPT Stock Alerts

Eyepoint Pharmaceuticals (EYPT) Financials

Eyepoint Pharmaceuticals logo
$3.05 +0.04 (+1.40%)
As of 12:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Eyepoint Pharmaceuticals

Annual Income Statements for Eyepoint Pharmaceuticals

This table shows Eyepoint Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 6.35 -22 -18 -86 -57 -91 -58 -102 -71 -131 -232
Consolidated Net Income / (Loss)		 6.35 -22 -18 -86 -57 -45 -58 -102 -71 -131 -232
Net Income / (Loss) Continuing Operations		 6.35 -22 -18 -86 -57 -91 -58 -102 -71 -131 -232
Total Pre-Tax Income 		6.44 -22 -18 -86 -57 -91 -58 -102 -71 -131 -232
Total Operating Income		 6.42 -22 -19 -39 -48 -37 -55 -100 -75 -146 -243
Total Gross Profit		 27 1.62 7.54 4.57 18 63 29 33 46 43 29
Total Revenue		 27 1.62 7.54 4.57 20 69 37 41 46 43 31
Operating Revenue		 27 1.62 7.54 4.57 20 69 37 41 46 43 31
Total Cost of Revenue		 0.00 0.00 0.00 0.00 2.69 5.82 8.18 8.33 0.00 0.00 2.07
Operating Cost of Revenue		 - - 0.00 - 2.69 5.82 8.18 8.33 - - 2.07
Total Operating Expenses		 20 23 26 44 66 138 84 133 121 189 273
Selling, General & Admin Expense		 8.06 9.01 11 15 18 21 26 35 40 52 52
Marketing Expense		 - 0.00 0.00 9.66 30 25 28 26 12 0.13 0.09
Research & Development Expense		 12 14 15 19 15 17 29 50 65 133 221
Amortization Expense		 - - 0.00 0.00 2.46 - 2.46 2.05 0.00 0.00 0.00
Impairment Charge		 - - - - - - 0.00 21 0.00 0.00 0.00
Total Other Income / (Expense), net		 0.02 0.07 0.09 -47 -8.93 -16 -3.14 -2.62 4.36 15 12
Interest Expense		 - 0.00 0.00 2.36 9.99 8.16 3.43 4.75 2.59 0.01 0.03
Other Income / (Expense), net		 0.02 0.07 0.09 -45 1.05 -8.05 0.29 2.13 6.95 15 12
Income Tax Expense		 0.10 -0.16 - - - - - 0.00 0.08 0.09 0.28
Basic Earnings per Share		 $0.22 ($0.68) ($0.52) ($1.27) ($5.44) ($3.54) ($2.03) ($2.74) ($1.82) ($2.32) ($3.17)
Weighted Average Basic Shares Outstanding		 29.38M 31.62M 35.34M 67.94M 10.43M 12.84M 28.76M 37.32M 38.90M 56.30M 73.25M
Diluted Earnings per Share		 $0.21 ($0.68) ($0.52) ($1.27) ($5.44) ($3.54) ($2.03) ($2.74) ($1.82) ($2.32) ($3.17)
Weighted Average Diluted Shares Outstanding		 30.58M 31.62M 35.34M 67.94M 10.43M 12.84M 28.76M 37.32M 38.90M 56.30M 73.25M
Weighted Average Basic & Diluted Shares Outstanding		 28.90M 31.62M 35.34M 67.94M 10.43M 12.84M 28.76M 34.30M 49.83M 68.73M 83.43M

Quarterly Income Statements for Eyepoint Pharmaceuticals

This table shows Eyepoint Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85 -94
Consolidated Net Income / (Loss)		 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85 -94
Net Income / (Loss) Continuing Operations		 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85 -94
Total Pre-Tax Income 		-14 -29 -31 -29 -41 -45 -59 -60 -67 -85 -94
Total Operating Income		 -16 -33 -35 -33 -45 -49 -62 -62 -70 -87 -97
Total Gross Profit		 18 11 9.48 9.79 14 24 5.17 0.97 -1.45 0.70 0.51
Total Revenue		 14 12 9.48 11 12 24 5.33 0.97 0.62 0.70 0.51
Operating Revenue		 14 12 9.48 11 12 24 5.33 0.97 0.62 0.70 0.51
Total Cost of Revenue		 -3.63 0.76 0.00 0.74 -2.90 0.81 0.17 0.00 2.07 0.00 0.00
Total Operating Expenses		 34 44 44 43 60 72 67 63 69 88 98
Selling, General & Admin Expense		 11 14 13 13 13 14 12 14 11 15 14
Marketing Expense		 0.19 0.01 0.05 0.02 0.05 0.04 0.04 0.03 -0.01 0.00 0.03
Research & Development Expense		 18 30 30 30 43 59 55 48 59 72 84
Other Operating Expenses / (Income)		 - - 1.40 - - - - 0.72 - 0.53 0.00
Total Other Income / (Expense), net		 2.34 4.04 3.72 3.39 3.93 3.64 2.89 2.29 2.92 2.34 2.91
Other Income / (Expense), net		 2.34 4.04 3.72 3.39 3.94 3.64 2.89 2.29 2.96 2.34 2.91
Income Tax Expense		 - - 0.00 0.00 - 0.00 0.09 0.00 - -0.05 0.00
Basic Earnings per Share		 ($0.32) ($0.55) ($0.58) ($0.54) ($0.65) ($0.65) ($0.85) ($0.85) ($0.82) ($0.99) ($1.09)
Weighted Average Basic Shares Outstanding		 38.90M 52.91M 53.21M 54.45M 56.30M 69.77M 69.93M 70.17M 73.25M 86.00M 86.54M
Diluted Earnings per Share		 ($0.32) ($0.55) ($0.58) ($0.54) ($0.65) ($0.65) ($0.85) ($0.85) ($0.82) ($0.99) ($1.09)
Weighted Average Diluted Shares Outstanding		 38.90M 52.91M 53.21M 54.45M 56.30M 69.77M 69.93M 70.17M 73.25M 86.00M 86.54M
Weighted Average Basic & Diluted Shares Outstanding		 49.83M 52.08M 53.52M 68.25M 68.73M 68.81M 68.93M 82.79M 83.43M 83.84M 86.21M

Annual Cash Flow Statements for Eyepoint Pharmaceuticals

This table details how cash moves in and out of Eyepoint Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 3.79 -3.81 1.59 22 -23 23 134 -83 186 -182 2.12
Net Cash From Operating Activities		 10 -16 -20 -22 -57 -14 -50 -65 1.88 -126 -240
Net Cash From Continuing Operating Activities		 10 -16 -20 -22 -57 -14 -50 -65 1.88 -126 -240
Net Income / (Loss) Continuing Operations		 6.35 -22 -18 -53 -57 -45 -58 -102 -71 -131 -232
Consolidated Net Income / (Loss)		 6.35 -22 -18 -53 -57 -45 -58 -102 -71 -131 -232
Depreciation Expense		 0.11 0.15 0.09 0.17 0.14 0.19 0.31 0.40 0.46 1.54 2.31
Amortization Expense		 0.87 0.84 -4.87 1.19 3.06 3.21 3.09 1.49 -0.86 -5.95 -4.83
Non-Cash Adjustments To Reconcile Net Income		 1.96 2.16 2.46 29 9.48 7.43 6.66 38 14 38 28
Changes in Operating Assets and Liabilities, net		 1.01 2.07 0.32 0.93 -13 20 -1.74 -3.09 59 -29 -34
Net Cash From Investing Activities		 -6.73 -4.46 14 -17 -0.21 -0.36 -33 -17 -3.32 -219 69
Net Cash From Continuing Investing Activities		 -6.73 -4.46 14 -17 -0.21 -0.36 -33 -17 -3.32 -219 69
Purchase of Property, Plant & Equipment		 -0.16 -0.11 -0.15 -0.11 -0.21 -0.36 -0.16 -2.15 -3.48 -4.05 -3.28
Purchase of Investments		 -10 -18 -5.05 0.00 - 0.00 -33 -139 -55 -398 -252
Sale of Property, Plant & Equipment		 0.00 0.00 0.03 0.00 - - - - - 0.00 0.16
Sale and/or Maturity of Investments		 3.65 13 19 0.00 - - 0.00 124 55 183 324
Net Cash From Financing Activities		 0.24 17 8.50 61 34 37 217 -0.69 187 164 174
Net Cash From Continuing Financing Activities		 0.24 17 8.50 61 34 37 217 -0.69 187 164 174
Repayment of Debt		 - 0.00 0.00 -1.35 -24 -15 0.00 -74 -47 0.00 0.00
Repurchase of Common Equity		 - - - - - - 0.00 -0.60 -0.45 -0.67 -0.54
Issuance of Debt		 - 0.00 0.00 20 50 - 0.00 74 5.30 0.00 0.00
Issuance of Common Equity		 0.00 17 8.40 42 23 50 217 0.00 226 163 173
Other Financing Activities, net		 0.24 0.49 0.10 0.50 -15 2.20 0.08 -0.04 3.17 1.38 0.75
Effect of Exchange Rate Changes		 -0.01 -0.02 - - - 0.00 0.00 0.00 0.00 0.00 0.00
Cash Interest Paid		 - 0.00 0.00 0.26 4.87 5.51 4.85 2.60 1.41 0.00 0.00

Quarterly Cash Flow Statements for Eyepoint Pharmaceuticals

This table details how cash moves in and out of Eyepoint Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 148 -10 -180 -11 20 -15 -14 3.43 27 -24 33
Net Cash From Operating Activities		 -23 -31 -20 -39 -36 -53 -63 -59 -65 -81 -62
Net Cash From Continuing Operating Activities		 -23 -31 -20 -39 -36 -53 -63 -59 -65 -81 -62
Net Income / (Loss) Continuing Operations		 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85 -94
Consolidated Net Income / (Loss)		 -14 -29 -31 -29 -41 -45 -59 -60 -68 -85 -94
Depreciation Expense		 0.11 0.30 0.36 0.41 0.47 0.50 0.54 0.58 0.70 0.64 0.69
Amortization Expense		 -0.52 -0.58 -1.69 -1.88 -1.81 -1.73 -1.20 -0.95 -0.94 -0.78 -0.19
Non-Cash Adjustments To Reconcile Net Income		 3.12 13 8.70 7.45 7.90 7.82 6.40 6.95 6.73 12 9.10
Changes in Operating Assets and Liabilities, net		 -12 -15 3.28 -16 -1.01 -15 -8.90 -6.20 -3.92 -7.21 23
Net Cash From Investing Activities		 -47 21 -160 16 -96 40 48 55 -75 59 75
Net Cash From Continuing Investing Activities		 -47 21 -160 16 -96 40 48 55 -75 59 75
Purchase of Property, Plant & Equipment		 -0.88 -1.19 -0.90 -1.57 -0.38 -0.28 -1.22 -0.80 -0.99 -1.00 -1.20
Sale and/or Maturity of Investments		 3.00 22 26 67 69 79 104 66 75 70 75
Net Cash From Financing Activities		 218 0.12 0.33 12 152 -0.95 0.24 7.40 167 -2.61 20
Net Cash From Continuing Financing Activities		 218 0.12 0.33 12 152 -0.95 0.24 7.40 167 -2.61 20
Repayment of Debt		 - 0.00 - -0.07 0.07 0.00 -0.05 0.05 - 0.00 -0.06
Repurchase of Common Equity		 -0.04 -0.09 0.09 -0.31 -0.37 -0.29 - - -0.25 -0.30 -0.09
Issuance of Common Equity		 216 0.00 - 12 152 0.00 - 6.66 167 0.00 20
Other Financing Activities, net		 2.32 0.20 0.55 0.17 0.46 -0.66 0.29 0.69 0.42 -2.32 0.52

Annual Balance Sheets for Eyepoint Pharmaceuticals

This table presents Eyepoint Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 32 32 19 78 73 92 263 180 355 418 364
Total Current Assets		 30 30 18 48 42 63 238 173 345 383 329
Cash & Equivalents		 19 15 17 45 22 45 179 96 281 100 102
Short-Term Investments		 9.41 14 - - - 0.00 33 49 50 271 204
Accounts Receivable		 0.62 0.49 0.25 0.63 11 9.45 18 16 0.81 0.61 0.65
Inventories, net		 - - 0.00 0.28 2.14 5.34 3.62 2.89 3.91 2.31 1.81
Prepaid Expenses		 0.68 0.48 0.59 1.43 6.00 3.42 4.22 9.86 9.04 9.48 20
Plant, Property, & Equipment, net		 0.34 0.29 0.31 0.29 0.36 0.63 0.48 1.36 5.25 8.18 9.02
Total Noncurrent Assets		 2.19 1.37 0.62 30 31 28 25 6.19 5.13 27 26
Intangible Assets		 1.93 1.10 0.36 30 28 25 23 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 0.12 0.11 0.11 0.00 3.08 2.61 2.25 6.04 4.98 27 26
Other Noncurrent Nonoperating Assets		 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
Total Liabilities & Shareholders' Equity		 32 32 19 78 73 92 263 180 355 418 364
Total Liabilities		 9.00 11 5.34 41 65 73 79 84 89 82 58
Total Current Liabilities		 3.35 5.09 5.29 21 12 15 24 35 63 49 37
Short-Term Debt		 - - - - - - 0.00 10 0.00 0.00 0.00
Accounts Payable		 0.74 1.36 1.02 2.64 4.19 4.81 7.39 5.92 6.50 12 10
Accrued Expenses		 2.57 3.58 4.22 19 6.83 8.45 14 16 18 18 24
Current Deferred Revenue		 0.03 0.15 0.05 0.03 0.02 0.95 1.07 1.21 39 18 0.00
Other Current Liabilities		 - - - 0.00 0.48 0.69 0.78 0.58 0.65 1.44 2.14
Total Noncurrent Liabilities		 5.65 5.65 0.05 19 53 58 55 49 26 33 21
Long-Term Debt		 - - 0.00 18 47 38 37 29 0.00 0.00 0.00
Noncurrent Deferred Revenue		 5.65 5.65 - - 0.00 16 15 14 21 11 0.00
Other Noncurrent Operating Liabilities		 - - 0.05 1.46 5.90 4.70 4.21 6.58 4.91 22 21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 23 21 13 38 8.33 19 184 96 266 337 306
Total Preferred & Common Equity		 23 21 13 38 8.33 19 184 96 266 337 306
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 23 21 13 38 8.33 19 184 96 266 337 306
Common Stock		 293 312 323 445 473 528 753 767 1,008 1,208 1,410
Retained Earnings		 -271 -292 -311 -408 -465 -511 -569 -671 -742 -873 -1,105
Accumulated Other Comprehensive Income / (Loss)		 0.95 0.85 0.83 0.84 0.84 0.84 0.84 0.79 0.86 1.03 0.96

Quarterly Balance Sheets for Eyepoint Pharmaceuticals

This table presents Eyepoint Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 155 176 160 329 324 301 363 301 252 288 228
Total Current Assets		 146 167 150 318 295 269 327 265 216 250 189
Cash & Equivalents		 106 140 133 271 91 80 85 71 75 78 110
Short-Term Investments		 17 2.94 2.98 28 189 174 233 185 129 145 70
Accounts Receivable		 10 11 0.48 3.02 1.38 0.38 0.44 0.63 1.05 1.16 0.09
Inventories, net		 4.07 4.26 4.58 4.26 3.67 2.81 2.13 2.68 2.11 1.25 1.88
Prepaid Expenses		 9.08 9.37 9.09 11 9.64 12 6.22 6.22 8.93 25 6.38
Plant, Property, & Equipment, net		 2.61 2.87 4.48 6.68 6.90 8.39 8.04 8.76 8.86 9.48 10
Total Noncurrent Assets		 5.93 5.66 5.40 4.86 22 24 28 27 27 29 29
Intangible Assets		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 5.78 5.51 5.25 4.71 22 24 27 27 27 29 29
Other Noncurrent Nonoperating Assets		 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
Total Liabilities & Shareholders' Equity		 155 176 160 329 324 301 363 301 252 288 228
Total Liabilities		 76 118 101 79 96 82 64 55 52 58 62
Total Current Liabilities		 27 69 64 63 62 49 42 33 30 37 42
Short-Term Debt		 5.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable		 9.45 11 9.58 7.08 14 7.34 16 20 10 19 17
Accrued Expenses		 10 15 13 16 13 14 18 11 18 16 22
Current Deferred Revenue		 1.24 42 40 38 33 26 5.12 0.00 0.00 0.00 0.00
Other Current Liabilities		 0.77 0.97 1.06 1.18 1.13 1.29 1.97 2.01 2.08 2.21 2.68
Total Noncurrent Liabilities		 49 49 38 17 34 33 22 22 21 20 20
Long-Term Debt		 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Noncurrent Deferred Revenue		 13 44 32 12 12 11 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 6.32 5.46 5.19 4.62 22 22 22 22 21 20 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 78 57 59 250 228 219 298 246 200 230 166
Total Preferred & Common Equity		 78 57 59 250 228 219 298 246 200 230 166
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 78 57 59 250 228 219 298 246 200 230 166
Common Stock		 770 772 786 1,021 1,030 1,049 1,216 1,223 1,237 1,419 1,450
Retained Earnings		 -693 -715 -728 -771 -802 -832 -918 -978 -1,037 -1,190 -1,284
Accumulated Other Comprehensive Income / (Loss)		 0.84 0.84 0.84 0.84 0.79 1.17 0.92 0.83 0.92 0.80 0.79

Annual Metrics And Ratios for Eyepoint Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eyepoint Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 29,412,365.00 34,172,919.00 39,268,692.00 94,855,705.00 108,117,440.00 143,515,338.00 28,771,264.00 - - - 82,787,220.00
DEI Adjusted Shares Outstanding		 2,941,236.00 3,417,292.00 3,926,869.00 9,485,570.00 10,811,744.00 14,351,534.00 28,771,264.00 - - - 82,787,220.00
DEI Earnings Per Adjusted Shares Outstanding		 2.16 -6.31 -4.71 -9.08 -5.25 -6.33 -2.03 - - - -2.80
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 6.33 -15 -13 -27 -34 -26 -39 -70 -53 -102 -170
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -19.73% -30.34% -55.67%
Earnings before Interest and Taxes (EBIT)		 6.44 -22 -18 -84 -47 -45 -55 -98 -68 -131 -232
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 7.42 -21 -23 -82 -44 -42 -52 -96 -69 -135 -234
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 8.14 -12 -18 -41 -57 -4.37 -36 -52 3.77 -132 -205
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.32 -8.26 -3.71 9.84 33 11 9.23 -8.56 -65 -35 -0.12
Increase / (Decrease) in Invested Capital		 -1.81 -2.94 4.55 14 23 -22 -2.23 -18 -56 30 34
Book Value per Share		 $0.79 $0.61 $0.34 $0.40 $0.08 $0.13 $6.41 $2.83 $7.54 $4.93 $3.70
Tangible Book Value per Share		 $0.73 $0.58 $0.33 $0.08 ($0.18) ($0.05) $5.62 $2.83 $7.54 $4.93 $3.70
Total Capital		 23 21 13 55 56 57 221 136 266 337 306
Total Debt		 0.00 0.00 0.00 18 47 38 37 40 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 18 47 38 37 29 0.00 0.00 0.00
Net Debt		 -29 -29 -17 -28 25 -6.93 -175 -105 -331 -371 -306
Capital Expenditures (CapEx)		 0.16 0.11 0.11 0.11 0.21 0.36 0.16 2.15 3.48 4.05 3.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.05 -4.12 -4.45 -19 7.98 3.32 2.53 4.19 -50 -37 -14
Debt-free Net Working Capital (DFNWC)		 26 25 12 26 30 48 214 149 282 334 292
Net Working Capital (NWC)		 26 25 12 26 30 48 214 138 282 334 292
Net Nonoperating Expense (NNE)		 -0.02 6.31 5.48 59 23 19 20 33 18 29 62
Net Nonoperating Obligations (NNO)		 -29 -29 -17 -28 25 -7.08 -175 -105 -331 -371 -306
Total Depreciation and Amortization (D&A)		 0.98 1.00 -4.78 1.36 3.20 3.39 3.40 1.89 -0.39 -4.41 -2.52
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.20 ($6.80) ($5.20) ($11.50) ($5.40) ($3.54) ($2.03) ($2.74) ($1.82) ($2.32) ($3.17)
Adjusted Weighted Average Basic Shares Outstanding		 2.94M 3.16M 3.53M 7.45M 12.47M 28.74M 34.04M 37.32M 38.90M 56.30M 73.25M
Adjusted Diluted Earnings per Share		 $2.10 ($6.80) ($5.20) ($11.50) ($5.40) ($3.54) ($2.03) ($2.74) ($1.82) ($2.32) ($3.17)
Adjusted Weighted Average Diluted Shares Outstanding		 3.06M 3.16M 3.53M 7.45M 12.47M 28.74M 34.04M 37.32M 38.90M 56.30M 73.25M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($5.20) ($11.50) ($5.40) ($3.54) ($2.03) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.94M 3.42M 3.94M 4.62M 10.43M 12.84M 28.76M 34.30M 49.83M 68.73M 83.43M
Normalized Net Operating Profit after Tax (NOPAT)		 6.33 -15 -13 -27 -34 -26 -39 -55 -53 -102 -170
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Eyepoint Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eyepoint Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - 68,728,760.00 68,811,736.00 68,927,425.00 82,787,220.00 83,431,950.00 83,841,298.00
DEI Adjusted Shares Outstanding		 - - - - - 68,728,760.00 68,811,736.00 68,927,425.00 82,787,220.00 83,431,950.00 83,841,298.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -0.66 -0.86 -0.87 -0.82 -1.02 -1.13
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 33.18% 52.08% 4.09% -30.77% -17.39% 109.29% -43.73% -90.82% - -97.15% -90.49%
EBITDA Growth		 66.20% -44.24% -52.71% -145.92% -195.56% -57.10% -86.58% -94.97% - -83.12% -56.63%
EBIT Growth		 67.15% -43.89% -45.83% -132.80% -194.63% -54.33% -92.48% -103.44% - -87.81% -59.22%
NOPAT Growth		 62.61% -54.59% -51.78% -127.45% -176.62% -46.57% -80.13% -89.40% - -78.61% -56.49%
Net Income Growth		 67.55% -38.37% -34.49% -132.80% -193.63% -54.33% -92.78% -103.44% - -87.70% -58.97%
EPS Growth		 72.41% 1.79% 4.92% -63.64% -103.13% -18.18% -46.55% -57.41% - -52.31% -28.24%
Operating Cash Flow Growth		 -83.58% -85.16% -135.39% -156.70% -55.13% -70.41% -210.18% -52.08% - -51.64% 0.39%
Free Cash Flow Firm Growth		 449.86% 67.31% -164.48% -175.76% -238.13% -482.93% -49.15% -14.38% - -39.15% 25.59%
Invested Capital Growth		 -658.09% -417.48% 39.02% 54.59% 46.73% 59.75% 81.05% 88.67% - 138.99% -43.92%
Revenue Q/Q Growth		 -7.72% -16.71% -18.89% 11.05% 10.11% 111.02% -78.19% -81.89% - 12.44% -27.16%
EBITDA Q/Q Growth		 -15.08% -104.88% -8.80% 4.13% -38.30% -8.90% -29.22% -0.19% - -25.71% -10.52%
EBIT Q/Q Growth		 -11.13% -108.93% -5.27% 4.75% -40.65% -9.44% -31.28% -0.67% - -25.96% -11.30%
NOPAT Q/Q Growth		 -13.59% -103.75% -3.68% 5.20% -38.14% -7.95% -27.42% 0.32% - -24.00% -11.64%
Net Income Q/Q Growth		 -11.79% -107.70% -5.27% 4.75% -41.00% -9.17% -31.49% -0.51% - -25.47% -11.36%
EPS Q/Q Growth		 3.03% -71.88% -5.45% 6.90% -20.37% 0.00% -30.77% 0.00% - -20.73% -10.10%
Operating Cash Flow Q/Q Growth		 -51.99% -34.89% 35.27% -93.42% 8.15% -48.18% -17.83% 5.17% - -23.83% 22.60%
Free Cash Flow Firm Q/Q Growth		 -47.90% -62.87% -445.18% -13.46% 5.02% -2.94% -34.44% 12.99% - -6.10% 28.11%
Invested Capital Q/Q Growth		 16.33% 23.60% -5.10% 32.41% 1.84% 42.28% 50.50% 59.59% - 6,422.76% -282.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 125.91% 93.50% 85.22% 93.01% 124.99% 100.00% 100.00% 100.00% - 100.00% 100.00%
EBITDA Margin		 -102.84% -252.96% -339.31% -292.94% -367.95% -189.88% -1,125.00% -6,222.26% - -12,216.09% -18,534.52%
Operating Margin		 -116.58% -285.18% -364.52% -311.17% -390.40% -199.72% -1,166.83% -6,420.81% - -12,532.47% -19,207.10%
EBIT Margin		 -99.91% -250.63% -325.27% -278.99% -356.36% -184.82% -1,112.56% -6,183.44% - -12,195.69% -18,633.14%
Profit (Net Income) Margin		 -100.51% -250.63% -325.27% -278.99% -357.26% -184.82% -1,114.31% -6,183.44% - -12,188.51% -18,633.14%
Tax Burden Percent		 100.59% 100.00% 100.00% 100.00% 100.22% 100.00% 100.16% 100.00% - 99.94% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.03% 100.00% 100.00% 100.00% - 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 -39.04% -48.07% -60.81% -74.68% -43.42% -53.54% -73.95% -98.23% - -102.71% -148.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -2,893.16% 0.00%
Operating Return on Assets (OROA)		 -17.17% -51.82% -65.58% -55.33% -39.87% -29.94% -184.65% -947.52% - -285.37% -196.28%
Return on Assets (ROA)		 -17.27% -51.82% -65.58% -55.33% -39.97% -29.94% -184.94% -947.52% - -285.21% -196.28%
Return on Common Equity (ROCE)		 -39.04% -48.07% -60.81% -74.68% -43.42% -53.54% -73.95% -98.23% - -102.71% -148.70%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -31.57% -38.03% -47.35% 0.00% -49.19% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -23 -24 -23 -32 -34 -44 -43 -49 -61 -68
NOPAT Margin		 -81.61% -199.63% -255.17% -217.82% -273.28% -139.80% -816.78% -4,494.57% - -8,772.73% -13,444.97%
Net Nonoperating Expense Percent (NNEP)		 -1.22% -3.08% -3.14% -3.30% -2.77% -3.56% -5.92% -7.12% - -8.79% -12.05%
Return On Investment Capital (ROIC_SIMPLE)		 -4.30% - - - -9.41% -11.46% -17.71% -21.69% -16.09% -26.49% -40.96%
Cost of Revenue to Revenue		 -25.91% 6.50% 14.78% 6.99% -24.99% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 80.18% 120.69% 134.54% 123.24% 108.19% 56.75% 222.43% 1,500.00% - 2,190.09% 2,809.07%
R&D to Revenue		 127.97% 257.95% 314.68% 280.71% 374.72% 239.54% 1,040.65% 4,943.48% - 10,366.09% 16,491.91%
Operating Expenses to Revenue		 242.49% 378.69% 449.74% 404.18% 515.39% 299.72% 1,266.83% 6,520.81% - 12,632.47% 19,307.10%
Earnings before Interest and Taxes (EBIT)		 -14 -29 -31 -29 -41 -45 -59 -60 -67 -85 -94
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -14 -30 -32 -31 -43 -46 -60 -60 -68 -85 -94
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.06 4.12 1.98 1.95 1.51 1.25 2.63 4.90 - 4.67 7.20
Price to Tangible Book Value (P/TBV)		 3.06 4.12 1.98 1.95 1.51 1.25 2.63 4.90 - 4.67 7.20
Price to Revenue (P/Rev)		 17.73 20.59 8.99 9.35 11.75 6.65 12.48 23.18 - 141.24 430.03
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 109.67 0.00
Enterprise Value to Revenue (EV/Rev)		 10.54 14.61 3.43 3.80 3.18 0.97 7.55 18.36 - 112.02 365.30
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 258.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 128.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -1.20 -1.18 -1.48 -1.41 -1.17 -1.13 -1.13 -1.09 - -1.02 -1.06
Leverage Ratio		 1.48 1.47 1.75 1.66 1.28 1.26 1.32 1.32 - 1.23 1.28
Compound Leverage Factor		 1.48 1.47 1.75 1.66 1.28 1.26 1.32 1.32 - 1.23 1.28
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 3.54 5.30 0.07 -0.04 1.54 0.63 2.95 5.93 - 5.33 3.18
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.45 5.08 4.75 5.50 7.81 7.85 8.00 7.18 - 6.66 4.50
Quick Ratio		 5.25 4.83 4.53 5.21 7.57 7.65 7.73 6.81 - 5.97 4.30
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 45 17 -58 -65 -62 -64 -86 -75 -84 -89 -64
Operating Cash Flow to CapEx		 -2,617.10% -2,610.64% -2,242.00% -2,479.54% -9,335.68% -19,246.38% -5,130.25% -7,437.84% - -8,079.14% -5,195.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -4,427.31 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -2,560.64 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -2,588.07 0.00 0.00 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.17 0.21 0.20 0.20 0.11 0.16 0.17 0.15 - 0.02 0.01
Accounts Receivable Turnover		 5.64 7.45 8.18 106.19 61.29 32.42 51.90 59.51 - 9.52 7.84
Inventory Turnover		 0.00 1.14 1.10 1.05 0.00 0.00 0.00 0.00 - 0.75 0.48
Fixed Asset Turnover		 13.92 10.77 10.31 7.10 6.45 7.61 6.63 4.91 - 0.87 0.30
Accounts Payable Turnover		 0.00 0.57 0.35 0.46 0.00 0.00 0.00 0.00 - 0.07 0.06
Days Sales Outstanding (DSO)		 64.67 49.03 44.64 3.44 5.96 11.26 7.03 6.13 - 38.33 46.54
Days Inventory Outstanding (DIO)		 0.00 319.90 332.06 346.07 0.00 0.00 0.00 0.00 - 489.03 759.31
Days Payable Outstanding (DPO)		 0.00 635.16 1,046.99 793.13 0.00 0.00 0.00 0.00 - 5,099.00 6,153.05
Cash Conversion Cycle (CCC)		 64.67 -266.23 -670.29 -443.63 5.96 11.26 7.03 6.13 - -4,571.64 -5,347.20
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -65 -50 -52 -35 -35 -20 -9.87 -3.99 -0.12 7.78 -14
Invested Capital Turnover		 -1.25 -1.69 -0.73 -0.81 -0.87 -1.61 -1.68 -2.16 - -1.25 -0.23
Increase / (Decrease) in Invested Capital		 -56 -40 33 42 30 30 42 31 34 28 -4.34
Enterprise Value (EV)		 485 731 173 174 138 54 392 778 - 853 1,018
Market Capitalization		 816 1,030 453 428 508 373 648 982 - 1,075 1,199
Book Value per Share		 $7.54 $5.02 $4.38 $4.09 $4.93 $4.34 $3.58 $2.90 $3.70 $2.76 $1.98
Tangible Book Value per Share		 $7.54 $5.02 $4.38 $4.09 $4.93 $4.34 $3.58 $2.90 $3.70 $2.76 $1.98
Total Capital		 266 250 228 219 337 298 246 200 306 230 166
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -331 -299 -280 -254 -371 -318 -256 -204 -306 -223 -180
Capital Expenditures (CapEx)		 0.88 1.19 0.90 1.57 0.38 0.28 1.22 0.80 0.99 1.00 1.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -50 -44 -47 -34 -37 -33 -24 -18 -14 -11 -34
Debt-free Net Working Capital (DFNWC)		 282 255 233 220 334 285 232 186 292 212 147
Net Working Capital (NWC)		 282 255 233 220 334 285 232 186 292 212 147
Net Nonoperating Expense (NNE)		 2.65 5.96 6.64 6.44 9.73 11 16 16 18 24 26
Net Nonoperating Obligations (NNO)		 -331 -299 -280 -254 -371 -318 -256 -204 -306 -223 -181
Total Depreciation and Amortization (D&A)		 -0.41 -0.27 -1.33 -1.47 -1.34 -1.24 -0.66 -0.38 -0.25 -0.14 0.50
Debt-free, Cash-free Net Working Capital to Revenue		 -107.59% -88.40% -94.10% -74.46% -84.71% -58.68% -45.58% -42.54% - -137.92% -1,205.09%
Debt-free Net Working Capital to Revenue		 611.80% 510.06% 462.04% 480.73% 772.44% 509.09% 447.18% 439.33% - 2,784.92% 5,268.08%
Net Working Capital to Revenue		 611.80% 510.06% 462.04% 480.73% 772.44% 509.09% 447.18% 439.33% - 2,784.92% 5,268.08%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.32) ($0.55) ($0.58) ($0.54) ($0.65) ($0.65) ($0.85) ($0.85) ($0.82) ($0.99) ($1.09)
Adjusted Weighted Average Basic Shares Outstanding		 38.90M 52.91M 53.21M 54.45M 56.30M 69.77M 69.93M 70.17M 73.25M 86.00M 86.54M
Adjusted Diluted Earnings per Share		 ($0.32) ($0.55) ($0.58) ($0.54) ($0.65) ($0.65) ($0.85) ($0.85) ($0.82) ($0.99) ($1.09)
Adjusted Weighted Average Diluted Shares Outstanding		 38.90M 52.91M 53.21M 54.45M 56.30M 69.77M 69.93M 70.17M 73.25M 86.00M 86.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.83M 52.08M 53.52M 68.25M 68.73M 68.81M 68.93M 82.79M 83.43M 83.84M 86.21M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -23 -24 -23 -32 -34 -44 -43 -49 -61 -68
Normalized NOPAT Margin		 -81.61% -199.63% -255.17% -217.82% -273.28% -139.80% -816.78% -4,494.57% - -8,772.73% -13,444.97%
Pre Tax Income Margin		 -99.91% -250.63% -325.27% -278.99% -356.48% -184.82% -1,112.56% -6,183.44% - -12,195.69% -18,633.14%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -2,949.64 0.00 0.00 0.00 - 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -2,261.95 0.00 0.00 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -2,977.07 0.00 0.00 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -2,289.38 0.00 0.00 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 -0.64% -0.68% -0.52% -0.33% -0.51% -0.60% -0.37% -0.32% - -0.20% -0.21%

Financials Breakdown Chart

Key Financial Trends

EyePoint Pharmaceuticals’ financial statements show a company with substantial liquidity but continued heavy investment and operating losses. The most recent quarter, Q2 2026, also highlights a widening gap between the company’s research spending and its currently limited commercial revenue.

  • Liquidity remains a meaningful buffer. EyePoint ended Q2 2026 with $110.5 million in cash and $70.0 million in short-term investments, or approximately $180.5 million in readily available funds. With $41.9 million of current liabilities and no short- or long-term debt reported, the company retained a current ratio of roughly 4.5.
  • Debt exposure is minimal. EyePoint reported zero short-term and long-term debt in Q2 2026. This limits interest expense and reduces the risk that rising cash needs will immediately translate into additional borrowing costs.
  • Investing activity supported cash in the latest quarter. The company generated $75.1 million from investing activities, primarily through the sale or maturity of $75.0 million of investments. As a result, cash and equivalents increased by $33.7 million during Q2 despite a substantial operating cash burn.
  • Operating cash burn improved sequentially. Net cash used in operating activities declined from $80.5 million in Q1 2026 to $62.3 million in Q2. This was still a significant outflow, but the improvement was helped by $22.5 million from changes in operating assets and liabilities.
  • Research spending indicates continued pipeline investment. Research and development expense rose to $83.6 million in Q2 2026 from $72.1 million in Q1 and $55.5 million in the restated Q2 2025 period. Although this hurts near-term earnings, the spending may support future product development and clinical progress.
  • Q2 financing provided an additional $20.0 million. EyePoint received $19.6 million from issuing common equity, partially offsetting its operating cash needs. This supports liquidity, but the benefit came through equity financing rather than internally generated cash.
  • Short-term investments are being converted into cash. Short-term investments fell from $233.0 million in Q1 2025 to $70.0 million in Q2 2026, while cash and equivalents increased from $85.2 million to $110.5 million over the same period. The shift improves immediate cash access, but it also means the company has a smaller investment reserve available to fund future operations.
  • Restated prior-period figures affect comparisons. Several 2024 and 2025 income statement and cash flow figures in the supplied data are identified as restated. Investors should rely on the restated figures when comparing periods and review company filings for the reasons behind those changes.
  • Revenue has declined sharply. Operating revenue fell to $507,000 in Q2 2026 from $696,000 in Q1 2026 and $5.3 million in restated Q2 2025. This is a substantial deterioration from $24.5 million in Q1 2025 and indicates that current revenue is not sufficient to support the company’s cost structure.
  • Net losses continue to widen. EyePoint reported a $94.5 million net loss in Q2 2026, compared with an $84.8 million loss in Q1 and a $59.4 million loss in restated Q2 2025. The quarterly loss equaled negative $1.09 per basic and diluted share.
  • Operating expenses are substantially higher than revenue. Total operating expenses reached $97.9 million in Q2 2026, including $83.6 million of research and development expense and $14.2 million of selling, general and administrative expense. Operating revenue covered only a small fraction of these costs, producing a $97.4 million operating loss.
  • Cash consumption remains high despite the liquidity cushion. EyePoint used $62.3 million in operating cash during Q2 2026 and $142.9 million during the first half of 2026. Continued losses at this pace could require additional investment sales, equity offerings or other financing before the company reaches sustainable operating cash flow.
  • The balance sheet has contracted materially. Total assets declined to $228.2 million in Q2 2026 from $362.6 million in Q1 2025 and $301.1 million in Q2 2024. Total equity also fell to $166.4 million from $230.5 million in Q1 2026, reflecting cumulative losses despite repeated equity issuances.
  • Shareholder dilution is an ongoing concern. EyePoint issued $19.6 million of common equity in Q2 2026, following a $167.0 million equity issuance in Q4 2025. Weighted-average basic shares increased to 86.5 million in Q2 2026 from 69.9 million in Q2 2025, reducing existing shareholders’ ownership percentage and increasing the number of shares over which future earnings must be spread.

Overall, EyePoint’s balance sheet provides near-term financial flexibility, supported by cash, investments and the absence of debt. However, the company remains highly dependent on its pipeline and future product commercialization because revenue is falling while research spending, net losses and operating cash burn remain elevated. The most important indicators for investors will be revenue recovery, progress toward lower cash burn and whether future funding can be obtained without substantial dilution.

10/15/26 12:10 PM ETAI Generated. May Contain Errors.

Eyepoint Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Eyepoint Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Eyepoint Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$231.96 million in 2025, compared with $6.35 million in 2015. The previous period was -$130.87 million in 2024. Check out Eyepoint Pharmaceuticals' forecast to explore projected trends and price targets.

Eyepoint Pharmaceuticals' total operating income in 2025 was -$243.43 million, based on the following breakdown:
  • Total Gross Profit: $29.31 million
  • Total Operating Expenses: $272.74 million

Over the last 10 years, Eyepoint Pharmaceuticals' total revenue changed from $26.57 million in 2015 to $31.37 million in 2025, a change of 18.1%.

In the past 13 quarters, Eyepoint Pharmaceuticals' cash and equivalents has ranged from $71.14 million in Q2 2025 to $271.01 million in Q1 2024, and is currently $110.46 million as of their latest financial filing in Q2 2026.

Eyepoint Pharmaceuticals had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Eyepoint Pharmaceuticals' book value per share changed from 0.79 in 2015 to 3.70 in 2025, a change of 365.4%.


Related Companies

Financial statements for NASDAQ:EYPT last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel